About this trial
Stroke remains one of the main socially significant problems in the healthcare in the third millennium. The lethality in persons with history of stroke by the end of the 1st year of disease is high. A trend to increased frequency of stroke in the young age is observed during the last decade; third of patients is working-age individuals, out of whom only 15-20% returns to labor, and others remain disabled persons requiring constant medical and social support
Eligibility criteria
Qualifiers
Signed informed consent form
Age from 18 years and older
Diagnosis: Acute cerebrovascular accident of ischemic type (ischemic stroke) developed within 36 hours before enrollment in the study
Motor neurologic deficit measurable using the NIHSS Scale (score for item 5 and/or 6 at the time of starting the therapy ≥ 1))
Disqualifiers
NIHSS 1a (coma) score 3 at the time of enrollment
Initial severe disablement (corresponding to mRS > 2) requiring external assistance in everyday life before development of stroke
History of Parkinson's disease, dementia, multiple sclerosis, and other significant diseases accompanied by neurologic deficit
Severe comorbidity with expected lifespan of not more than 6 months
Trial design
Treatments tested in this trial
- Cytoflavin